Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Capital Expenditures (2016 - 2025)

Angiodynamics (ANGO) has disclosed Capital Expenditures for 16 consecutive years, with $333000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 71.39% year-over-year to $333000.0, compared with a TTM value of $3.1 million through Nov 2025, down 13.97%, and an annual FY2025 reading of $4.5 million, up 77.28% over the prior year.
  • Capital Expenditures was $333000.0 for Q4 2025 at Angiodynamics, down from $820000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.2 million in Q2 2021 and bottomed at -$3.9 million in Q1 2022.
  • Average Capital Expenditures over 5 years is $912300.0, with a median of $814500.0 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 250.71% in 2021, while the deepest fall reached 282.84% in 2021.
  • Year by year, Capital Expenditures stood at $2.7 million in 2021, then plummeted by 52.87% to $1.3 million in 2022, then tumbled by 54.88% to $578000.0 in 2023, then soared by 101.38% to $1.2 million in 2024, then plummeted by 71.39% to $333000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ANGO at $333000.0 in Q4 2025, $820000.0 in Q3 2025, and $596000.0 in Q2 2025.